Literature DB >> 30623822

Clinical characteristics associated with the discrepancy between subjective and objective cognitive impairment in depression.

J Z Petersen1, R J Porter2, K W Miskowiak3.   

Abstract

BACKGROUND: Patients with unipolar disorder (UD) commonly experience cognitive dysfunction during symptomatic and remitted phases. However, it is not necessarily the patients with the greatest subjective complaints, who display the largest objectively-measured deficits on neuropsychological tests.
OBJECTIVE: This report investigated the demographic and clinical factors associated with the discrepancy between subjective and objective measures of cognition in two separate depressed patient populations in Denmark and New Zealand, respectively, using a new methodology.
METHODS: Data from 137 depressed patients and 103 healthy controls including neuropsychological test scores, self-reported cognitive difficulties, and ratings of mood were pooled from two studies conducted in Copenhagen, Denmark, and Christchurch, New Zealand, respectively. Cognitive discrepancy scores were calculated using a novel methodology, with positive values indicating disproportionately more subjective than objective difficulties (i.e., "sensitivity") and negative values indicating more objective than subjective impairments (i.e., "stoicism").
RESULTS: In the Danish partially remitted patient sample, greater 'sensitivity' was associated with more subsyndromal depression severity (standardized Beta (std. β )= 0.4, p < 0.01)), illness duration (std. β = 0.4, p < 0.01), and younger age (std. β = 0.6, p < 0.001). This association was replicated in the New Zealand sample of more symptomatic patients (p-values ≤ 0.05). LIMITATIONS: The cross-sectional design hampered causal inferences. We had obtained different measures of objective and subjective cognition from the two studies.
CONCLUSIONS: Patients with more depressive symptoms and younger age overreported cognitive impairments across all illness states. The use of an objective cognition screener thus seems particularly relevant for these patients to assess whether subjective complaints are accompanied by measurable cognitive deficits.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognition; Cognitive dysfunction; Depression; Neuropsychology; Objective; Subjective; Unipolar disorder

Mesh:

Year:  2018        PMID: 30623822     DOI: 10.1016/j.jad.2018.12.105

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  11 in total

1.  In pursuit of full recovery in major depressive disorder.

Authors:  Vicent-Gil M; Serra-Blasco M; Navarra-Ventura G; Trujols J; Balanzá-Martínez V; Portella Mj; Cardoner N
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-09-09       Impact factor: 5.760

2.  Predictors of Long-Term Improvement Following Cognitive Remediation in a Sample With Elevated Depressive Symptoms.

Authors:  Bjørn Ingulfsvann Hagen; Nils Inge Landrø; Bjørn Lau; Ernst H W Koster; Jan Stubberud
Journal:  Front Psychol       Date:  2020-09-11

3.  Clinical and methodological considerations for psychological treatment of cognitive impairment in major depressive disorder.

Authors:  Katie M Douglas; Melissa Milanovic; Richard J Porter; Christopher R Bowie
Journal:  BJPsych Open       Date:  2020-06-29

4.  Is cognitive dysfunction involved in difficult-to-treat depression? Characterizing resistance from a cognitive perspective.

Authors:  Clara López-Solà; Marta Subirà; Maria Serra-Blasco; Muriel Vicent-Gil; Guillem Navarra-Ventura; Eva Aguilar; Siddarta Acebillo; Diego J Palao; Narcís Cardoner
Journal:  Eur Psychiatry       Date:  2020-06-23       Impact factor: 5.361

5.  Neuropsychological, Medical, and Psychiatric Findings After Recovery From Acute COVID-19: A Cross-sectional Study.

Authors:  Stephen J Ferrando; Rhea Dornbush; Sean Lynch; Sivan Shahar; Lidia Klepacz; Carol L Karmen; Donald Chen; Stephen A Lobo; Dania Lerman
Journal:  J Acad Consult Liaison Psychiatry       Date:  2022-01-25

Review 6.  Influences of dopaminergic system dysfunction on late-life depression.

Authors:  Warren D Taylor; David H Zald; Jennifer C Felger; Seth Christman; Daniel O Claassen; Guillermo Horga; Jeffrey M Miller; Katherine Gifford; Baxter Rogers; Sarah M Szymkowicz; Bret R Rutherford
Journal:  Mol Psychiatry       Date:  2021-08-17       Impact factor: 15.992

7.  Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): recruitment, retention, and data availability in a longitudinal remote measurement study.

Authors:  Faith Matcham; Daniel Leightley; Sara Siddi; Femke Lamers; Katie M White; Peter Annas; Giovanni de Girolamo; Sonia Difrancesco; Josep Maria Haro; Melany Horsfall; Alina Ivan; Grace Lavelle; Qingqin Li; Federica Lombardini; David C Mohr; Vaibhav A Narayan; Carolin Oetzmann; Brenda W J H Penninx; Stuart Bruce; Raluca Nica; Sara K Simblett; Til Wykes; Jens Christian Brasen; Inez Myin-Germeys; Aki Rintala; Pauline Conde; Richard J B Dobson; Amos A Folarin; Callum Stewart; Yatharth Ranjan; Zulqarnain Rashid; Nick Cummins; Nikolay V Manyakov; Srinivasan Vairavan; Matthew Hotopf
Journal:  BMC Psychiatry       Date:  2022-02-21       Impact factor: 3.630

8.  Long-term subjective memory after electroconvulsive therapy.

Authors:  Robert Sigström; Axel Nordenskjöld; Anders Juréus; Caitlin Clements; Erik Joas; Erik Pålsson; Mikael Landén
Journal:  BJPsych Open       Date:  2020-03-09

9.  Executive dysfunction in schizophrenia: Predictors of the discrepancy between subjective and objective measures.

Authors:  Ingvild Haugen; Jan Stubberud; Torill Ueland; Elisabeth Haug; Merete Glenne Øie
Journal:  Schizophr Res Cogn       Date:  2021-06-15

10.  Correlates of the discrepancy between objective and subjective cognitive functioning in non-demented patients with Parkinson's disease.

Authors:  Mattia Siciliano; Lugi Trojano; Rosa De Micco; Valeria Sant'Elia; Alfonso Giordano; Antonio Russo; Luca Passamonti; Gioacchino Tedeschi; Carlo Chiorri; Alessandro Tessitore
Journal:  J Neurol       Date:  2021-03-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.